Company: IMRX
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001790340-25-000135
Chunk: 337

Company: Immuneering Corp
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 337
---
251,3495,251 —— 23,388,922 — — 23,394,173 Issuance of common stock through public offering, net of underwriting discounts and $0.4 million in offering costs18,959,91418,960 —— 164,068,015 — — 164,086,975 Issuance of common stock through private placement with Aventis Inc., net of placement agent discounts and $0.2 million in placement costs.2,708,5592,709 —— 23,297,291 — — 23,300,000 Stock-based compensation expense—— —— 1,456,080 — — 1,456,080 Net loss—— —— — — (14,964,875)(14,964,875)Balance at September 30, 202563,483,397$63,483 —$— $496,653,023 $— $(268,740,074)$227,976,432 

9

Table of Contents

Class A Common StockClass B Common StockAdditionalPaid-In CapitalAccumulated OtherComprehensive Income (Loss)AccumulatedDeficitTotalStockholders' EquitySharesPar ValueSharesPar ValueBalance at December 31, 202329,271,629$29,272 —$— $253,806,267 $(778)$(163,258,578)$90,576,183 Issuance of common stock upon exercise of stock options229,299229 —— 732,229 — — 732,458 Issuance of common stock through employee stock purchase plan152,427152 —— 247,313 — — 247,465 Stock-based compensation expense—— —— 1,474,758 — — 1,474,758 Net loss—— —— — — (14,307,829)(14,307,829)Other comprehensive income—— —— — (306)— (306)Balance at March 31, 202429,653,355$29,653 —$— $256,260,567 $(1,084)$(177,566,407)$78,722,729 Stock-based compensation expense—— —— 1,661,749 — — 1,661,749 Net loss——